Skip to main content
Premium Trial:

Request an Annual Quote

Florida Upholds Orchid Cellmark Contract

NEW YORK (GenomeWeb News) – Orchid Cellmark said today that the Florida Department of Revenue has upheld a contract that had been awarded to the firm to conduct all publicly funded paternity testing for the State of Florida.
 
The Princeton, NJ-based firm said that the contract had been awarded late last year but was held up by protest of the award by Laboratory Corporation of America, which formerly had provided paternity testing to the state. An administrative law judge oversaw a three-day trial in April, and the Department of Revenue’s decision is based on the findings from those proceedings, said Orchid.
 
The multi-year contract begins Sept. 1 and is extendable for an additional three years beyond its expiration in 2011. Orchid President and CEO Thomas Bologna said in a statement that the contract is worth approximately $1.2 million per year.
 
Orchid noted that it previously provided the State of Florida with roughly one-third of its paternity testing services, while LabCorp had serviced the remaining two-thirds of the state.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.